Cargando…

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer

Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase inhibitor (TKI) treatment. However, clinical trials of several TKIs failed to prove efficacy. In this context, we investigated changes in MAPK signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knievel, Judith, Schulz, Wolfgang A., Greife, Annemarie, Hader, Christiane, Lübke, Tobias, Schmitz, Ingo, Albers, Peter, Niegisch, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264180/ https://www.ncbi.nlm.nih.gov/pubmed/25387078 http://dx.doi.org/10.3390/ijms151120500

Ejemplares similares

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Canonical Notch signalling is inactive in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines
por: Lang, Alexander, et al.
Publicado: (2020)

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma
por: Kreimer, Ulrike, et al.
Publicado: (2013)

Contingencies of UTX/KDM6A Action in Urothelial Carcinoma
por: Lang, Alexander, et al.
Publicado: (2019)

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014)

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer
por: Whongsiri, Patcharawalai, et al.
Publicado: (2020)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2015)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2017)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells
por: Heubach, Judith, et al.
Publicado: (2015)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells
por: Koutsogiannouli, Evangelia A., et al.
Publicado: (2017)

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
por: Wang, Chenyin, et al.
Publicado: (2020)

The role of c-FLIP splice variants in urothelial tumours
por: Ewald, F, et al.
Publicado: (2011)

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2022)

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
por: Hoffmann, Michèle J., et al.
Publicado: (2016)

The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells
por: Nikpour, Parvaneh, et al.
Publicado: (2011)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
por: Kaletsch, Aline, et al.
Publicado: (2018)

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2019)

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2019)

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
por: Berning, Lena, et al.
Publicado: (2021)

Microvesicles: the functional mediators in sorafenib resistance
por: He, Cong, et al.
Publicado: (2022)

Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1
por: Erichsen, Lars, et al.
Publicado: (2020)

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors
por: Hoffmann, Michèle J., et al.
Publicado: (2015)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Expression of G1→S Transition Regulatory Molecules in Human Urothelial Cancer
por: Oya, Mototsugu, et al.
Publicado: (1998)

Comparative Analysis of Elderly Patients Undergoing Radical Cystectomy With Ureterocutaneostomy or Ileal Conduit With a Special Focus on Bowl Complications Requiring Surgical Revision
por: Mally, David, et al.
Publicado: (2022)

Cognitive function in patients undergoing cystectomy for bladder cancer – results from a prospective observational study
por: Grunewald, Camilla M., et al.
Publicado: (2022)

Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
por: Niegisch, Günter
Publicado: (2018)

A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany
por: Niegisch, Günter, et al.
Publicado: (2018)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0o3lab915jsaauboev9bi6cc29